title: Upmodulation of alpha v beta 1 integrin expression on human tumor cells by human interleukin for DA cells/leukemia inhibitory factor and oncostatin M: correlation with increased cell adhesion on fibronectin.
abstract: Integrins belong to a large family of heterodimeric membrane glycoproteins which mediate cell-cell or cell-extracellular matrix interactions. These interactions could play a major role during the migration of tumor cells across the extracellular matrix and vascular endothelium and would thus appear to be requisite for the metastatic process. Pretreatment of the Foss human melanoma cell line with HILDA/LIF or OSM, two cytokines involved in acute-phase response, increased the expression of membrane alpha v beta 1 1.5-2-fold. The same phenomenon was observed on the SK-N-SH human neuroblastoma cell line. alpha v beta 1 upmodulation was concomitant with improved tumor cells attachment to the fibronectin matrix. This greater adhesion of tumor cells to fibronectin was inhibited by specific monoclonal antibodies against alpha v or beta 1 integrin subunits. Similar results were obtained after TNF-alpha treatment. Our findings demonstrate the ability of HILDA/LIF and OSM to modulate tumor cell capacity to adhere to the matrix component, suggesting a potential role for these cytokines in modulation of tumoral progression.
authors.affiliation: I.N.S.E.R.M. U211, Institute of Biology, Nantes, France.
authors.forename: D
authors.initials: D
authors.lastname: Heymann
authors.forename: J
authors.initials: J
authors.lastname: Harb
authors.forename: S
authors.initials: S
authors.lastname: Ringeard
authors.forename: F
authors.initials: F
authors.lastname: Blanchard
authors.forename: D
authors.initials: D
authors.lastname: Lassort
authors.forename: S
authors.initials: S
authors.lastname: Raher
authors.forename: A
authors.initials: A
authors.lastname: Godard
mesh_terms: D002448:Cell Adhesion / Q000187:drug effects; D005353:Fibronectins / Q000378:metabolism; D006131:Growth Inhibitors / Q000494:pharmacology* / Q000502:physiology; D006801:Humans; D016023:Integrins / Q000378:metabolism*; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000494:pharmacology* / Q000502:physiology; D008545:Melanoma / Q000473:pathology / Q000503:physiopathology; D009361:Neoplasm Invasiveness / Q000503:physiopathology; D053683:Oncostatin M; D010455:Peptides / Q000494:pharmacology* / Q000502:physiology; D019030:Receptors, Vitronectin; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D005353:Fibronectins; D006131:Growth Inhibitors; D016023:Integrins; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; C508351:OSM protein, human; D010455:Peptides; D019030:Receptors, Vitronectin; D014409:Tumor Necrosis Factor-alpha; C094340:integrin alphavbeta1; D053683:Oncostatin M